CN Patent

CN1209358C — αLβ2介导细胞粘连的抑制剂

Assigned to Tanabe Pharma Corp · Expires 2005-07-06 · 21y expired

What this patent protects

本发明涉及根据式(I)的小分子，它们是α L β 2 介导细胞粘连的有效抑制剂，能够用于治疗炎性疾病。

USPTO Abstract

本发明涉及根据式(I)的小分子，它们是α L β 2 介导细胞粘连的有效抑制剂，能够用于治疗炎性疾病。

Drugs covered by this patent

Patent Metadata

Patent number
CN1209358C
Jurisdiction
CN
Classification
—
Expires
2005-07-06
Drug substance claim
No
Drug product claim
No
Assignee
Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.